OXILAN-300 Drug Patent Profile

Which patents cover Oxilan-300, and when can generic versions of Oxilan-300 launch?

Oxilan-300 is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in OXILAN-300 is ioxilan. There is one drug master file entry for this compound. Additional details are available on the ioxilan profile page.

Summary for OXILAN-300

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	48
Patent Applications:	1,502
DailyMed Link:	OXILAN-300 at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for OXILAN-300

V08AB	Watersoluble, nephrotropic, low osmolar X-ray contrast media
V08A	X-RAY CONTRAST MEDIA, IODINATED
V08	CONTRAST MEDIA
V	Various

US Patents and Regulatory Information for OXILAN-300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Guerbet	OXILAN-300	ioxilan	INJECTABLE;INJECTION	020316-001	Dec 21, 1995		DISCN	No	No

Expired US Patents for OXILAN-300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Guerbet	OXILAN-300	ioxilan	INJECTABLE;INJECTION	020316-001	Dec 21, 1995

International Patents for OXILAN-300

See the table below for patents covering OXILAN-300 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6197486
Australia	6686690
Norway	178106
Norway	871474
Australia	600672
European Patent Office	0233249	MILIEUX DE CONSTRASTE NON-IONIQUES A BASE DE POLYOL OBTENUS A PARTIR DE MILIEUX DE CONTRASTE IONIQUES. (NON-IONIC POLYOL CONTRAST MEDIA FROM IONIC CONTRAST MEDIA.)
Canada	1339666	AGENT DE CONTRASTE NON IONIQUE A POLYOL OBTENU A PARTIR D'UNE SUBSTANCE DE CONTRASTE IONIQUE (NON-IONIC POLYOL CONTRAST MEDIA FROM IONIC CONTRAST MEDIA)